Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C

Abstract

TLR may be a powerful marker to predict PTR of HCC patients with BCLC stage C who were treated with conversion therapy.